Ray Therapeutics

Ray TherapeuticsRay Therapeutics
Ray Therapeutics

Ray Therapeutics

Pioneering vision restoration therapies for severe retinal degenerations.

Website
DR 292021ActiveBerkeley, USA
Rate
Advertise here

About

Ray Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies to restore vision for individuals suffering from severe retinal degenerations. Their approach aims to address unmet medical needs in ophthalmology.
Frequently asked

What does Ray Therapeutics do?

Ray Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies to restore vision for individuals suffering from severe retinal degenerations. Their approach aims to address unmet medical needs in ophthalmology.

What is Ray Therapeutics's revenue?

StartupHub estimates Ray Therapeutics's annual revenue at $38.1M (range $12.7M to $107.9M, 34% confidence), based on comparable companies in the sector.

What is Ray Therapeutics's valuation?

StartupHub estimates Ray Therapeutics's effective valuation at $932.0M (range $607.5M to $1.5B, 24% confidence), based on comparable companies in the sector.

How much funding has Ray Therapeutics raised?

Ray Therapeutics has raised a total of $243M in funding. The most recent round on record is Series B.

Where is Ray Therapeutics headquartered?

Ray Therapeutics is headquartered in Berkeley, California, USA.

When was Ray Therapeutics founded?

Ray Therapeutics was founded in 2021.

What industry does Ray Therapeutics operate in?

Ray Therapeutics operates in Biotechnology, Pharmaceuticals, Healthcare, Medical Devices, Biotech, Drug Discovery.

Comments

No comments yet. Be the first to share your take.